Document


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 12, 2018

biogenlogostandard.jpg
Biogen Inc.
(Exact name of registrant as specified in its charter)
Delaware
0-19311
33-0112644
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)

225 Binney Street, Cambridge, Massachusetts 02142
(Address of principal executive offices; Zip Code)
    
Registrant’s telephone number, including area code: (617) 679-2000
Not Applicable
(Former name or former address, if changed since last report.)
    
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

¨ Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨











Item 5.07     Submission of Matters to a Vote of Security Holders

On June 12, 2018, Biogen Inc. (the "Company") held its 2018 Annual Meeting of Stockholders. The final voting results for this meeting are as follows:

1.
Stockholders elected eleven nominees to the Board of Directors to serve for a one-year term extending until the 2019 annual meeting of stockholders and their successors are duly elected and qualified, with the votes cast as follows:
Nominee
 
Votes For
 
Votes Against
 
Abstentions
 
Broker Non-Votes
Alexander J. Denner
 
157,681,261

 
9,664,386

 
576,090

 
14,573,630

Caroline D. Dorsa
 
157,434,403

 
9,677,268

 
810,066

 
14,573,630

Nancy L. Leaming
 
158,893,984

 
8,217,493

 
810,260

 
14,573,630

Richard C. Mulligan
 
159,714,555

 
7,630,683

 
576,499

 
14,573,630

Robert W. Pangia
 
155,816,805

 
11,325,013

 
779,919

 
14,573,630

Stelios Papadopoulos
 
153,686,995

 
12,454,094

 
1,780,648

 
14,573,630

Brian S. Posner
 
158,057,511

 
9,047,930

 
816,296

 
14,573,630

Eric K. Rowinsky
 
158,363,760

 
8,668,825

 
889,152

 
14,573,630

Lynn Schenk
 
156,698,182

 
10,413,299

 
810,256

 
14,573,630

Stephen A. Sherwin
 
159,567,535

 
7,533,951

 
820,251

 
14,573,630

Michel Vounatsos
 
158,958,201

 
8,143,565

 
819,971

 
14,573,630



2.
Stockholders ratified the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018, with the votes cast as follows:
Votes For
 
Votes Against
 
Abstentions
 
Broker Non-Votes
180,175,118
 
1,979,549
 
340,700
 
-


3.
Stockholders approved the advisory vote on executive compensation, with the votes cast as follows:
Votes For
 
Votes Against
 
Abstentions
 
Broker Non-Votes
158,785,398
 
7,670,851
 
1,465,488
 
14,573,630
 

4.
A stockholder proposal requesting certain proxy access bylaw amendments was not approved, with the votes cast as follows:
Votes For
 
Votes Against
 
Abstentions
 
Broker Non-Votes
47,675,995
 
118,395,156
 
1,850,586
 
14,573,630


5.
A stockholder proposal requesting a report on the extent to which risks related to public concern over drug pricing strategies are integrated into incentive compensation arrangements was not approved, with the votes cast as follows:
Votes For
 
Votes Against
 
Abstentions
 
Broker Non-Votes
46,608,359
 
118,636,079
 
2,677,299
 
14,573,630





Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Biogen Inc.
By: /s/ James Basta
James Basta
Chief Corporation Counsel and Assistant Secretary
Date: June 14, 2018